On March 18, 2026, Indaptus Therapeutics, Inc. reported multiple executive resignations including co-CEO David Lazar and appointed Junyi Dai as the new CEO and Chairman. The company noted a significant stock transaction resulting in an aggregate purchase of $11.2 million for convertible preferred stock, potentially increasing common stock ownership significantly.